Skip to main content
Terug
Watch Compare

Protara Therapeutics, Inc.

Datakwaliteit: 83%
TARA
Nasdaq Manufacturing Chemicals
€ 4,96
▼ € 0,35 (-6,59%)
Marktkapitalisatie: 285,02 M
Prijs
€ 5,27
Marktkapitalisatie
285,02 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -56,46 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-41,52%
Boven sectorgemiddelde (-53,41%)
ROIC-36,18%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio13,69
Interest CoverageN/A

Waardering

PE (TTM)
-4,96
Onder sectorgemiddelde (-1,48)
P/B Ratio2,15
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -5,0 -1,5
P/B 2,2 1,6
ROE % -41,5 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BRSIX BRSIX
0,17% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,01% weight
AVSCX AVSCX
0,01% weight
VVICX VVICX
0,01% weight
IIRSX IIRSX
0,01% weight
IRSIX IRSIX
0,01% weight
IRCIX IRCIX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -57,44 M
ROE -41,52% ROA -38,09%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -56,46 M
ROIC -36,18% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 13,69
Interest Coverage N/A Asset Turnover N/A
Working Capital 125,74 M Tangible Book Value 132,29 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,96 Forward P/E N/A
P/B Ratio 2,15 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19,81%
Market Cap 285,02 M Enterprise Value 272,47 M
Per Share
EPS (Diluted TTM) -1,34 Revenue / Share N/A
FCF / Share -1,04 OCF / Share -1,04
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 98,29%
SBC-Adj. FCF -60,17 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -57,44 M -44,60 M -40,42 M -65,95 M -47,25 M
EPS (Diluted) -1,34 -2,17 -3,57 -5,86 —
Gross Profit — — — — —
Operating Income -64,55 M -49,15 M -43,61 M -67,06 M -47,49 M
EBITDA — — — — —
R&D Expenses 42,63 M 31,70 M 24,99 M 16,81 M 21,09 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — 0,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 209,47 M 181,45 M 78,95 M 113,29 M 172,60 M
Total Liabilities 13,06 M 14,32 M 10,63 M 11,21 M 10,68 M
Shareholders' Equity 196,41 M 167,13 M 68,32 M 102,08 M 161,91 M
Total Debt — — — — —
Cash & Equivalents 49,66 M 162,80 M 39,59 M 24,13 M 35,72 M
Current Assets 159,50 M 172,16 M 68,71 M 86,15 M 93,11 M
Current Liabilities 10,94 M 10,96 M 6,15 M 5,74 M 4,30 M